TerminatedPhase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
Reason given: sponsor closed study down
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of California San FranciscoSan Francisco, United StatesNo longer taking part
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT02523092
- Record updated
- 30 April 2026
- Original description
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).Read full original descriptionShow less
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Inclusion: Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement; Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate.
Exclusion: Recent surgery; Cancer; Chronic infections (e.g. tuberculosis, viral, fungal, bacterial); Inflammatory conditions; Coexisting lung disease; Congestive heart failure; Uncontrolled hypertension; Smoking; Active peptic ulcers; Osteoporosis.